This research study is being done to learn more about the short term and long term side effects of treatment with asparaginase drugs, which are commonly used in acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy) therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Probability of developing CTCAE grade 3+ (3, 4, 5) or 4+ (4, 5) toxicities during standard of care (SOC) therapy
Timeframe: Approximately 2½ to 3 years
Probability of developing CTCAE grade 3+ (3, 4, 5) or 4+ (4, 5) toxicities SJALL23T therapy
Timeframe: Approximately 2½ to 3 years
Cumulative incidence (CIN) of the grade 3+ or 4+ toxicities throughout SOC therapy
Timeframe: Approximately 2½ to 3 years
Cumulative incidence (CIN) of the grade 3+ or 4+ toxicities throughout SJALL23T therapy
Timeframe: Approximately 2½ to 3 years
Probabilities of grade 3+ or 4+ toxicities each phase of SOC treatment
Timeframe: Approximately 2½ to 3 years
Probabilities of grade 3+ or 4+ toxicities each phase of SJALL23Ttreatment
Timeframe: Approximately 2½ to 3 years